Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase of Trial: Phase II/III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Venglustat (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Registrational; Therapeutic Use
- Acronyms SAVE-PKD; STAGED-PKD
- Sponsors Sanofi; Sanofi Genzyme; Sanofi K.K.
- 12 Jul 2019 Planned End Date changed from 1 Dec 2022 to 1 Jan 2023.
- 12 Jul 2019 Planned primary completion date changed from 1 Dec 2022 to 1 Jan 2023.
- 06 Dec 2018 Planned End Date changed from 1 Nov 2022 to 1 Dec 2022.